SEC Filing Summary: Bellevue Life Sciences Acquisition Corp. (BLAC)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Bellevue Life Sciences Acquisition Corp. (BLAC) is a Special Purpose Acquisition Company (SPAC) incorporated in Delaware. The Company has not commenced operations and is seeking to consummate a business combination with OSR Holdings Co., Ltd. ("OSR Holdings"). The Company is classified as an emerging growth company and a shell company. As of the filing date, the Company has extended its deadline to complete a business combination to February 14, 2025.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Net Loss (Income) | $(230,961) | $(388,686) | $489,952 |
| General & Administrative Expenses | $454,132 | $1,380,457 | $968,806 |
| Interest Income (Trust Account) | $269,204 | $1,215,533 | $1,846,529 |
| Cash (Operating Account) | $12,236 | $12,236 | $57,955 |
| Investments in Trust Account | $20,886,019 | $20,886,019 | $36,605,106 |
| Working Capital Deficit | $(3,901,465) | $(3,901,465) | N/A |
| Related Party Debt | $1,778,000 | $1,778,000 | $0 |
Note: The Company has no operating revenue. Income is derived solely from interest on Trust Account investments.
Material Changes vs. Prior Period
- Trust Account Reduction: The Trust Account balance decreased from $36.6 million (Dec 31, 2023) to $20.9 million (Sep 30, 2024). This reduction is primarily due to significant share redemptions totaling approximately $53 million across two special meetings in November 2023 and May 2024.
- Share Count: Shares subject to possible redemption decreased from 3,467,954 to 1,886,221 due to redemptions.
- Related Party Borrowings: The Company incurred $1.778 million in related party promissory notes during the period to fund working capital and extension payments, compared to zero outstanding at the end of 2023.
- Profitability Shift: The Company reported a net loss for the nine months ended September 30, 2024, contrasting with a net income in the same period in 2023, driven by lower interest income and higher administrative expenses.
Outlook, Risks, and Contingencies
- Business Combination: BLAC has entered into an Amended and Restated Business Combination Agreement with OSR Holdings. The transaction is subject to stockholder approval and a minimum cash condition of $5,000,001.
- Pipeline Financing (PIPE): On October 4, 2024, the Company signed a subscription agreement with Toonon Partners Co., Ltd. for a $20 million PIPE investment in Series A Preferred Stock, contingent on the closing of the business combination.
- Liquidity and Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern. With only $12,236 in operating cash and a working capital deficit of $3.9 million, the Company relies on loans from the Sponsor and affiliates to fund operations until the business combination or liquidation date (February 14, 2025).
- Nasdaq Compliance: The Company previously failed to meet the minimum 300 public holders requirement. While a hearing panel granted continued listing until February 17, 2025, recent redemptions at the November 12, 2024 Annual Meeting further reduced public holders, creating risk for future compliance.
- Internal Controls: The Company disclosed material weaknesses in internal controls over financial reporting regarding the use of funds withdrawn from the Trust Account for general expenses and insufficient accounting personnel.
- Excise Tax: The Company has accrued a $530,415 liability for the 1% excise tax on stock repurchases under the Inflation Reduction Act.
Investor Verification Checklist
- Redemption Impact: Verify the current number of public holders post-November 2024 redemptions to assess the risk of Nasdaq delisting before the February 2025 deadline.
- PIPE Closing Conditions: Confirm the status of the $20 million PIPE investment with Toonon Partners and whether the $5 million minimum cash condition for the OSR Holdings deal can be met.
- Related Party Debt Forgiveness: Review the terms of the $1.778 million in related party notes; these are generally forgivable if the business combination fails, but repayment is required if the deal closes.
- Extension Payments: Monitor the Company's ability to fund monthly extension payments ($50,000/month) into the Trust Account to maintain the deadline through February 2025.
- Internal Control Remediation: Assess the Company's plan to remediate the material weaknesses in financial reporting identified in the filing.